In the third quarter, our revenue were $1 billion, driven by sales of our fully approved vaccines, Spikevax, mNEXSPIKE, ...
Net Sales Growth of ~44% Year-Over-Year $75 Million of Debt Repaid in Fiscal 2025 Cash Provided by Operating Activities Increased ~86% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback